Do we need a vaccine against chikungunya?

Area of Science:

• Virology
• Vaccinology
• Public Health

Background:

• Chikungunya virus (CHIKV) has expanded globally, posing a significant public health threat.
• The emergence of CHIKV in the Americas highlights the urgent need for a safe and effective vaccine.
• Current vaccine research for CHIKV has progressed slowly but shows promise.

Purpose of the Study:

• To review the current status of chikungunya vaccine development.
• To identify challenges and key factors for successful chikungunya vaccine trials and availability.

Main Methods:

• Review of existing literature on chikungunya vaccine candidates.
• Analysis of phase I/II trial results for inactivated, attenuated, and engineered vaccines.
• Examination of virus-like particle (VLP) vaccine development.
• Discussion of logistical and financial considerations for large-scale clinical trials.

Main Results:

• Inactivated and attenuated CHIKV vaccine candidates show promise in early trials.
• Engineered vaccines are safe and immunogenic in preclinical models.
• A VLP-based vaccine candidate has successfully completed phase I trials.
• Large-scale efficacy trials require epidemic conditions and significant investment.

Conclusions:

• Several chikungunya vaccine candidates demonstrate potential for efficacy and safety.
• Successful large-scale trials and vaccine availability depend on strategic planning, funding, and public-private partnerships.
• Addressing chikungunya as a neglected tropical disease requires sustained support for vaccine development and accessibility.